Selected articles
Articles for label Bartoušková Marie are displayed.. Show all articles
Atezolizumab in breast cancer therapy
02/2020 MUDr. Nikol Rušarová; MUDr. Marie Bartoušková
Breast cancer is the most frequently diagnosed cancer of women (except of skin tumors). In addition, up to 30 percent of women with early-stage, non-metastatic breast cancer at diagnosis will develop distant metastatic disease. Currently due to preventive examinations and mammography examination the incidence of breast cancer is increasing, which was 146 women / 100 000 inhabitants in 2017. But mortality decreases due to new possibilities of treatment and enlargement of the treatment armamentarium. In 2017 the mortality rate was 34.7 women / 100 000 inhabitants.
ENTIRE ARTICLE
Breast cancer is the most frequently diagnosed cancer of women (except of skin tumors). In addition, up to 30 percent of women with early-stage, non-metastatic breast cancer at diagnosis will develop distant metastatic disease. Currently due to preventive examinations and mammography examination the incidence of breast cancer is increasing, which was 146 women / 100 000 inhabitants in 2017. But mortality decreases due to new possibilities of treatment and enlargement of the treatment armamentarium. In 2017 the mortality rate was 34.7 women / 100 000 inhabitants.
Current treatment management of metastatic HER-2+/HER-2- breast cancer
02/2019 MUDr. Nikol Rušarová, MUDr. Marie Bartoušková, doc. MUDr. David Vrána, Ph.D.
Breast cancer is the most frequently diagnosed cancer and despite the gains in early detection, up to 5 percent of women are diagnosed with metastatic disease at the time of first presentation. Due to development of new molecules breast cancer is now a chronic disease, while metastatic disease is still incurable. It is a heterogeneous diverse disease composed of several biologic subtypes that have distinct behaviors and responses to therapy.
ENTIRE ARTICLE
Breast cancer is the most frequently diagnosed cancer and despite the gains in early detection, up to 5 percent of women are diagnosed with metastatic disease at the time of first presentation. Due to development of new molecules breast cancer is now a chronic disease, while metastatic disease is still incurable. It is a heterogeneous diverse disease composed of several biologic subtypes that have distinct behaviors and responses to therapy.